Syngene International Ltd.
NSE: SYNGENE · Healthcare Research, Analytics & Technology
Snapshot
Unlock Syngene International Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Syngene International Limited is a contract research, development, and manufacturing organisation (CRDMO) providing integrated scientific services to the pharmaceutical, biotechnology, and specialty chemical sectors. The company supports the entire drug discovery and development lifecycle, ranging from early-stage research to commercial-scale manufacturing.
Business Model
The company operates on a service-based model, offering discovery chemistry, biology, and development services through long-term partnerships and project-based contracts. Revenue is generated by providing technical expertise, infrastructure, and regulatory support to global life sciences clients.
- Incorporation Year:1993
- Parent Company:Biocon Limited
Management Commentary
Management focuses on expanding capabilities in advanced drug modalities such as PROTACs, antibody-drug conjugates, and CAR T-cell therapies to maintain a competitive edge. The company leverages strategic collaborations with global pharmaceutical leaders to drive innovation and operational scale.
Growth Outlook
Growth is driven by the increasing global demand for outsourced R&D and manufacturing services, alongside the expansion of high-value service offerings. The company continues to invest in infrastructure to support complex biological and chemical development projects.
Key Risks
- Regulatory Compliance. Failure to adhere to stringent international regulatory standards for drug development and manufacturing could result in loss of business or legal penalties.
- Client Concentration. Significant reliance on long-term partnerships with a limited number of major pharmaceutical companies poses a risk if these relationships are terminated.
- Intellectual Property Risk. The nature of contract research involves handling sensitive client data and proprietary information, where any breach could severely damage the company's reputation.
- Geopolitical and Currency Risk. As a global service provider, the company is exposed to fluctuations in foreign exchange rates and potential changes in international trade policies.
Start your research today
Unlock AI insights, financials, peers and live data on Syngene International Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,600 Cr
TTM · consolidated
NET PROFIT
₹221 Cr
TTM · consolidated
EPS
₹5.50
TTM · consolidated
RETURN ON EQUITY
4.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.2%
TTM · consolidated
P/E
71.9x
Q1 FY27 · consolidated
EV/EBITDA
17.9x
Q1 FY27 · consolidated
EBITDA MARGIN
24.5%
TTM · consolidated
NET PROFIT MARGIN
-1.2%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Syngene International Ltd.SYNGENE | ₹15,969 Cr | 71.93 | 17.87 | -3.4% | 24.5% | 4.6% | 6.2% | -39.8% |
Indegene Ltd.INDGN | ₹14,493 Cr | 36.00 | 19.80 | 30.4% | 18.8% | 13.9% | 17.4% | +10.6% |
Suven Life Sciences LimitedSUVEN | ₹10,681 Cr | -25.39 | -30.90 | 17.3% | -557.4% | -100.5% | -99.8% | +78.6% |
Vimta LabsVIMTALABS | ₹2,839 Cr | 35.59 | 18.05 | 15.2% | 37.3% | 19.1% | 24.1% | -20.2% |
Fabtech Technologies LimitedFABTECH | ₹668 Cr | 10.87 | 9.14 | — | 16.3% | 11.6% | 14.1% | — |
Take SolutionsTAKE | ₹204 Cr | 16.07 | 32.77 | — | 7.4% | 49.8% | 24.2% | +27.3% |
As of Q1 FY27
Financials
Syngene International Ltd.
NSE: SYNGENE · Healthcare Research, Analytics & Technology
Snapshot
Unlock Syngene International Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Syngene International Limited is a contract research, development, and manufacturing organisation (CRDMO) providing integrated scientific services to the pharmaceutical, biotechnology, and specialty chemical sectors. The company supports the entire drug discovery and development lifecycle, ranging from early-stage research to commercial-scale manufacturing.
Business Model
The company operates on a service-based model, offering discovery chemistry, biology, and development services through long-term partnerships and project-based contracts. Revenue is generated by providing technical expertise, infrastructure, and regulatory support to global life sciences clients.
- Incorporation Year:1993
- Parent Company:Biocon Limited
Management Commentary
Management focuses on expanding capabilities in advanced drug modalities such as PROTACs, antibody-drug conjugates, and CAR T-cell therapies to maintain a competitive edge. The company leverages strategic collaborations with global pharmaceutical leaders to drive innovation and operational scale.
Growth Outlook
Growth is driven by the increasing global demand for outsourced R&D and manufacturing services, alongside the expansion of high-value service offerings. The company continues to invest in infrastructure to support complex biological and chemical development projects.
Key Risks
- Regulatory Compliance. Failure to adhere to stringent international regulatory standards for drug development and manufacturing could result in loss of business or legal penalties.
- Client Concentration. Significant reliance on long-term partnerships with a limited number of major pharmaceutical companies poses a risk if these relationships are terminated.
- Intellectual Property Risk. The nature of contract research involves handling sensitive client data and proprietary information, where any breach could severely damage the company's reputation.
- Geopolitical and Currency Risk. As a global service provider, the company is exposed to fluctuations in foreign exchange rates and potential changes in international trade policies.
Start your research today
Unlock AI insights, financials, peers and live data on Syngene International Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,600 Cr
TTM · consolidated
NET PROFIT
₹221 Cr
TTM · consolidated
EPS
₹5.50
TTM · consolidated
RETURN ON EQUITY
4.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.2%
TTM · consolidated
P/E
71.9x
Q1 FY27 · consolidated
EV/EBITDA
17.9x
Q1 FY27 · consolidated
EBITDA MARGIN
24.5%
TTM · consolidated
NET PROFIT MARGIN
-1.2%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
As of Q1 FY27